ENP
ENTROPY NEURODYNAMIC ORDINARYEntropy Neurodynamics Limited, a clinical-stage pharmaceutical development company, focuses on developing formulations for the administration of psilocin in combination with psychotherapy to treat diseases with unmet medical needs in Australia, Canada, Switzerland, and the United States. The company's lead program candidate is TRP-8803, a formulation of IV-infused psilocin that completed Phase 2 clinical trial for the treatment of binge eating disorder, fibromyalgia, irritable bowel syndrome, abdominal pain, and visceral tenderness. It is also involved in the development of TRP-8802, a synthetic and oral psilocybin currently under phase 2a clinical trial for the treatment of binge eating, as well as under phase 2 clinical stage for the treatment of fibromyalgia and irritable bowel syndrome. The company was formerly known as Tryptamine Therapeutics Limited and changed its name to Entropy Neurodynamics Limited in November 2025. Entropy Neurodynamics Limited was founded in 2019 and is based in Camberwell, Australia.
ENP
ENP
ENTROPY NEURODYNAMIC ORDINARY
Entropy Neurodynamics Limited, a clinical-stage pharmaceutical development company, focuses on developing formulations for the administration of psilocin in combination with psychotherapy to treat diseases with unmet medical needs in Australia, Canada, Switzerland, and the United States. The company's lead program candidate is TRP-8803, a formulation of IV-infused psilocin that completed Phase 2 clinical trial for the treatment of binge eating disorder, fibromyalgia, irritable bowel syndrome, abdominal pain, and visceral tenderness.
Fundamentals
Historical Data63 days
| Date | Short % | Gross Short |
|---|---|---|
| 16 July | — | — |
| 15 July | — | — |
| 14 July | — | — |
| 13 July | 0.00% | — |
| 10 July | 0.00% | — |
| 9 July | 0.00% | — |
| 8 July | 0.00% | — |
| 7 July | 0.00% | — |
| 6 July | 0.00% | — |
| 3 July | 0.00% | — |
| 2 July | 0.00% | — |
| 1 July | 0.00% | — |
Entropy Neurodynamic (ENP) Short Interest Summary
Entropy Neurodynamic (ENP) currently has 0.00% of its shares sold short (0 thousand shares, worth approximately $0K), based on ASIC short position data reported on 13 July 2026 (T+4 reporting lag). That makes ENP the #739 most shorted stock on the ASX most shorted list. Short interest in ENP is up 0.00% over the past week and up 0.00% over the past month. ENP is part of the Health Care sector on the ASX.
Recent ENP Short Position History
| Date | Short % | Short Shares | Close Price |
|---|---|---|---|
| 13 July 2026 | 0.00% | 0.0M | $0.03 |
| 10 July 2026 | 0.00% | 0.0M | $0.04 |
| 9 July 2026 | 0.00% | 0.0M | $0.03 |
| 8 July 2026 | 0.00% | 0.0M | $0.03 |
| 7 July 2026 | 0.00% | 0.0M | $0.03 |
| 6 July 2026 | 0.00% | 0.0M | $0.03 |
| 3 July 2026 | 0.00% | 0.0M | $0.03 |
| 2 July 2026 | 0.00% | 0.0M | $0.03 |
| 1 July 2026 | 0.00% | 0.0M | $0.03 |
| 30 June 2026 | 0.00% | 0.0M | $0.03 |
ENP Short Selling — Frequently Asked Questions
What is Entropy Neurodynamic (ENP)'s current short interest?
Entropy Neurodynamic (ENP) currently has a short interest of 0.00% of total shares outstanding. This means 0.00% of ENP's shares have been sold short by investors who expect the price to decline. This data is sourced from ASIC reports and updated daily.
Is ENP heavily shorted on the ASX?
ENP has a relatively low short interest of 0.00%. Short interest below 5% generally suggests limited bearish sentiment from short sellers.
What does short interest mean for ENP investors?
Short interest in ENP shows the percentage of shares investors have borrowed and sold, betting the price will fall. At 0.00%, ENP's short interest is at a low level. See our short squeeze candidates and days to cover analysis for more context.
Where does this ENP short data come from?
Short position data is published by ASIC with a four trading day delay (T+4) and covers reported short positions as a percentage of total shares on issue. ASX Short Data also tracks daily gross short sales (T+1), securities lending, and director trades for ENP.